Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Shanghai Junshi Bioscience Co., Ltd.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Trans Tasman Radiation Oncology Group
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Jewish General Hospital
Jewish General Hospital
Alliance for Clinical Trials in Oncology
University of California, San Francisco
Alliance for Clinical Trials in Oncology
Trans Tasman Radiation Oncology Group
New Mexico Cancer Research Alliance
Fred Hutchinson Cancer Center
University of Washington
Peking University Cancer Hospital & Institute
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
Mayo Clinic
City of Hope Medical Center
SCRI Development Innovations, LLC
Fox Chase Cancer Center
Mayo Clinic